3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
46
Colorectal Neoplasms
33
Stomach Neoplasms
31
Esophageal Squamous Cell Carcinoma
27
Esophageal Neoplasms
14
Rectal Neoplasms
12
Cholangiocarcinoma
11
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Neoplasm Metastasis
6
Sarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Locally Advanced Rectal Cancer
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Melanoma
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
HER2-positive Gastric Cancer
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Interventions
Cyclophosphamide
4
pembrolizumab
3
Nivolumab
3
regorafenib
2
fludarabine
2
SS1(dsFv)PE38
2
Ipilimumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Decitabine
2
Cisplatin
2
tislelizumab
1
sodium thiosulfate
1
sargramostim
1
entinostat
1
durvalumab
1
cemiplimab
1
bemcentinib
1
avelumab
1
atezolizumab
1
alvocidib
1
alanosine
1
X-Rays
1
Tetrahydrouridine
1
Tamoxifen
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Referral and Consultation
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
tislelizumab
×
Gastrointestinal
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn